Paul J Feustel1, Yiqiang Jin, Harold K Kimelberg. 1. Center for Neuropharmacology and Neuroscience, MC136, Albany Medical College, Albany, New York, USA. feustep@mail.amc.edu
Abstract
BACKGROUND AND PURPOSE: Release of excitatory amino acids (EAA) is considered a cause of neuronal damage in ischemia. We investigated the sources and mechanisms of EAA release using microdialysis in regions of incomplete ischemia where perfusion was reduced by 50% to 80%, by applying inhibitors of volume-regulated anion channels (VRACs) and the GLT-1 glutamate transporter. METHODS: Reversible middle cerebral artery occlusion (rMCAo) was induced in anesthetized rats using the intraluminal suture technique. Microdialysate concentrations of glutamate, aspartate, and taurine were measured before, during 2 hours of rMCAo, and for 2 hours after rMCAo. Vehicle, dihydrokainate (DHK, 1 mmol/L), a GLT-1 inhibitor, or tamoxifen (50 micromol/L), a VRAC inhibitor, were administered continuously via the dialysis probes starting one hour prior to ischemia. RESULTS: During incomplete ischemia, dialysate glutamate levels averaged 1.74+/-0.31 micromol/L (SEM) in the control group (n=8), 2.08+/-0.33 micromol/L in the DHK group (n=7), and were significantly lower at 0.88+/-0.30 micromol/L in the tamoxifen group (n=9; P<0.05). As perfusion returned toward baseline levels, EAA levels declined in the vehicle and tamoxifen-treated animals but they remained elevated in the DHK-treated animals. CONCLUSIONS: In contrast to previous results in severely ischemic regions, DHK did not reduce EAA release in less severely ischemic brain, suggesting a diminished role for transporter reversal in these areas. These findings also support the hypothesis that in regions of incomplete ischemia, release of EAAs via VRACs may play a larger role than reversal of the GLT-1 transporter.
BACKGROUND AND PURPOSE: Release of excitatory amino acids (EAA) is considered a cause of neuronal damage in ischemia. We investigated the sources and mechanisms of EAA release using microdialysis in regions of incomplete ischemia where perfusion was reduced by 50% to 80%, by applying inhibitors of volume-regulated anion channels (VRACs) and the GLT-1glutamate transporter. METHODS: Reversible middle cerebral artery occlusion (rMCAo) was induced in anesthetized rats using the intraluminal suture technique. Microdialysate concentrations of glutamate, aspartate, and taurine were measured before, during 2 hours of rMCAo, and for 2 hours after rMCAo. Vehicle, dihydrokainate (DHK, 1 mmol/L), a GLT-1 inhibitor, or tamoxifen (50 micromol/L), a VRAC inhibitor, were administered continuously via the dialysis probes starting one hour prior to ischemia. RESULTS: During incomplete ischemia, dialysate glutamate levels averaged 1.74+/-0.31 micromol/L (SEM) in the control group (n=8), 2.08+/-0.33 micromol/L in the DHK group (n=7), and were significantly lower at 0.88+/-0.30 micromol/L in the tamoxifen group (n=9; P<0.05). As perfusion returned toward baseline levels, EAA levels declined in the vehicle and tamoxifen-treated animals but they remained elevated in the DHK-treated animals. CONCLUSIONS: In contrast to previous results in severely ischemic regions, DHK did not reduce EAA release in less severely ischemic brain, suggesting a diminished role for transporter reversal in these areas. These findings also support the hypothesis that in regions of incomplete ischemia, release of EAAs via VRACs may play a larger role than reversal of the GLT-1 transporter.
Authors: Alexander A Mongin; María C Hyzinski-García; Melanie Y Vincent; Richard W Keller Journal: Am J Physiol Cell Physiol Date: 2011-07-06 Impact factor: 4.249
Authors: Arjun Khanna; Kristopher T Kahle; Brian P Walcott; Volodymyr Gerzanich; J Marc Simard Journal: Transl Stroke Res Date: 2013-11-22 Impact factor: 6.829
Authors: Guanghong Liao; Miou Zhou; Simon Cheung; James Galeano; Nam Nguyen; Michel Baudry; Xiaoning Bi Journal: Brain Res Date: 2008-11-01 Impact factor: 3.252
Authors: Huaqiu Zhang; Minjie Xie; Gary P Schools; Paul F Feustel; Wei Wang; Ting Lei; Harold K Kimelberg; Min Zhou Journal: Brain Res Date: 2008-11-01 Impact factor: 3.252